Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Chengdu SciMount Pharmatech Co., Ltd.

Clinicaltrial registered6 Nov 2026

Chengdu SciMount Pharmatech Co., Ltd.

6 Nov 2026: Trial registered · A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
6 Nov 2026
Title
A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors
Conditions
HER2-Expressing Advanced Solid Tumors, HER2-Mutated Advanced Solid Tumors, Metastatic Solid Tumors
Phase
Phase 1
Study Type
Interventional
Status
Completed
Countries
China
Country
China
Reference
NCT07922096
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Chengdu SciMount Pharmatech Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.